Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

(2016) P Stopfer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans

(2015) Nicolas Hohmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies

(2015) Lichuan Liu et al.   JOURNAL OF CLINICAL PHARMACOLOGY

The Use of Transporter Probe Drug Cocktails for the Assessment of Transporter-Based Drug–Drug Interactions in a Clinical Setting—Proposal of a Four Component Transporter Cocktail

(2015) Thomas Ebner et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects

(2014) Sreeneeranj Kasichayanula et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin

(2014) Thomayant Prueksaritanont et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling

(2014) Sieto Bosgra et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective

(2013) Thomayant Prueksaritanont et al.   AAPS Journal

Physiologically based pharmacokinetic modelling andin vivo[I]/Kiaccurately predict P-glycoprotein-mediated drug-drug interactions with dabigatran etexilate

(2013) Yuansheng Zhao et al.   BRITISH JOURNAL OF PHARMACOLOGY

In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development

(2013) K L R Brouwer et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effect of a single-dose rifampin on the pharmacokinetics of pitavastatin in healthy volunteers

(2013) Yao Chen et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin

(2012) Xavier Delavenne et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Transporter-Mediated Drug–Drug Interactions Involving OATP Substrates: Predictions Based on In Vitro Inhibition Studies

(2012) K Yoshida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver

(2012) Evita van de Steeg et al.   JOURNAL OF CLINICAL INVESTIGATION

Nonlinear Pharmacokinetics of Oral Quinidine and Verapamil in Healthy Subjects: A Clinical Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Identification of the Rate-Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

(2011) K Maeda et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments

(2011) T. Watanabe et al.   DRUG METABOLISM AND DISPOSITION

Effect of Cytochrome P450 3A5 Genotype on Atorvastatin Pharmacokinetics and Its Interaction with Clarithromycin

(2011) Jaekyu Shin et al.   PHARMACOTHERAPY

Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data

(2010) I Templeton et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Membrane transporters in drug development

(2010)   NATURE REVIEWS DRUG DISCOVERY

Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism

(2009) Yi-Jing He et al.   CLINICA CHIMICA ACTA

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin

(2009) S. K. Quinney et al.   DRUG METABOLISM AND DISPOSITION

Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs

(2009) Ichiro Ieiri et al.   Expert Opinion on Drug Metabolism & Toxicology